Clinical Outcomes in Patients with Triple-negative Breast Cancer and Brain Metastases.
10.4048/jbc.2010.13.2.160
- Author:
Hyuk Chan KWON
1
;
Sung Yong OH
;
Sung Hyun KIM
;
Suee LEE
;
Kyung A KWON
;
Ji Hyun LEE
;
Mi Ri LEE
;
Se Heon CHO
;
Young Jin CHOI
;
Hyo Jin KIM
Author Information
1. Medical Research Center for Cancer Molecular Therapy, Dong-A University College of Medicine, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Brain metastasis;
Breast neoplasms;
Triple negative
- MeSH:
Brain;
Breast;
Breast Neoplasms;
Disease-Free Survival;
Estrogens;
Humans;
Neoplasm Metastasis;
Receptors, Progesterone;
Retrospective Studies
- From:Journal of Breast Cancer
2010;13(2):160-166
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Patients with triple-negative breast cancer (TNBC) are known to carry an increased risk of distant metastasis and poor survival. The principal objective of this study was to investigate survival after brain metastases in patients with TNBC. METHODS: The authors retrospectively evaluated clinical data obtained from 66 patients who had been diagnosed with breast cancer and brain metastasis from 2003 to 2009. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor-2 (HER2) statuses were determined via immunohistochemical staining. TNBCs were defined as those that were ER-negative, PR-negative, and HER2-negative. The time interval from initial diagnosis to brain metastasis and overall survival after brain metastasis was evaluated via the Kaplan-Meier method. RESULTS: Twenty four (40.0%) of 60 patients were diagnosed with TNBC. The clinicopathologic characteristics did not differ between the TNBC and non-TNBC patients. The disease-free survival durations of the TNBC and non-TNBC subjects were 17.9 and 25.6 months, respectively (p=0.135). The time intervals from initial diagnosis to brain metastasis were 25.5 and 43.7 months, respectively (p=0.027). The time intervals from distant metastasis to brain metastasis were 8.4 and 19.5 months, respectively (p=0.006). Overall survival durations from brain metastasis to death were 4.3 and 7.6 months, respectively (p=0.046). CONCLUSION: Patients with TNBC were more likely to develop brain metastasis earlier, and exhibit poor overall survival. Triple receptor status may be utilized as a prognostic marker for breast cancer patients with brain metastasis.
